To counter resistance and improve patient survival rates, the oncology research community is actively exploring combinations of EGFR-TKIs with other therapeutic modalities, including chemotherapies, monoclonal antibodies, immunotherapies, and pathway inhibitors, aiming for a synergistic effect in combating NSCLC [19]. Here, EGFR is linked to non-small cell lung carcinoma.